Do the results of the GEPAR trials indicate that PMRT based on pre-neoadjuvant chemo risk factors, irrelevant of pCR, should be the standard of care until NSABP B-51 is completed?  

The GEPAR trials presented at ASCO 2015 showed increased LRR with the omission of RT in patients who had a pCR after neoadjuvant chemotherapy.



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Varian Medical Systems/Allegheny health network
More recent Dutch data (Lancet 2022) with tailored...
Sign in or Register to read more